Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparison of infections in patients with chronic lymphocytic leukemia (CLL) treated with BTKi versus venetoclax obinutuzumab in first line therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ZBZubair Hassan Bodla

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows increased infection rates in CLL patients treated with BTKi, implying BTKi may have higher risks than venetoclax obinutuzumab.

Key Points

  • The aim is to compare infection rates and overall survival between CLL patients treated with BTKi and venetoclax obinutuzumab.
  • Retrospective analysis using TriNteX database with data from 148 healthcare organizations.
  • Patients with CLL were divided into two groups based on treatment: BTKi and venetoclax-obinutuzumab.
  • Infection rates were compared using risk ratio and overall survival was assessed through Kaplan-Meier analysis.
  • Higher infection rates were observed in BTKi patients for bacterial pneumonia, urinary tract infections, and diverticulitis.
  • The median overall survival was 9.5 years for BTKi and was not reached for venetoclax group.
  • BTKi patients had significantly higher rates of infections compared to the venetoclax group.

Cite This Study

Zubair Hassan Bodla (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d86chttps://doi.org/10.1182/blood-2025-3884
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of bruton tyrosine kinase inhibitors versus venetoclax in chronic lymphocytic leukemia.2026
  2. 2Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group2026
  3. 3Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  4. 4Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia2024 · 9 citations
  5. 5Real-world overall survival outcomes of BTK inhibitors vs. venetoclax-based therapy as second-line treatment for chronic lymphocytic leukemia.2026